BDR Pharma launches Nintenib to treat idiopathic pulmonary fibrosis in India

BDR Pharmaceutical has announced the launch of 100mg and 150 mg nintedanib under the brand name Nintenib for the treatment of idiopathic pulmonary fibrosis (IPF). Nintenib is priced at Rs. 750 (100 mg) and Rs. 900 (150 mg) for a pack of 10 tabs.
Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosi

The median survival in IPF patients is 2.5 to 3.5 years. Nintedanib received Drugs Controller General of India (DCGI) approval after showing a significant slowdown in the disease progression in patients with pulmonary fibrosis by reducing the rate of decline in forced vital capacity (FVC) in patients with IPF and mild or moderate lung function impairment.

Currently, there are two clinical trials being conducted to study the safety and efficacy of nintedanib for the treatment of moderately to critically ill COVID-19 patients suffering from IPF.

Dharmesh Shah, CMD, BDR Pharmaceuticals said, “We are thrilled to innovate and work towards introducing newer, effective and affordable treatment options for patients. We are proud to launch the generic version of the drug for lung fibrosis in India especially during a time when there is an ardent need of the medicine for COVID-19 patients. We are happy to lend our hand in any way to ensure the community is better prepared during this pandemic. With the launch of nintedanib, we are on the verge of changing the therapeutic dynamics in the segment of tyrosine kinase inhibitors”.

Nintedanib is a small molecule tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) involved in signaling pathways which lead to its use in pulmonary fibrosis. It has also shown significant efficacy in the management of non-small cell carcinoma of the lung as well as systemic sclerosis.

BDR is recognized as a niche player in manufacturing of pharmaceutical APIs and for the renowned new age formulations. BDR Group of companies has grown steadily in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life Sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.

BDR Group focuses on development in 6 specialized therapeutic segments, viz. oncology, critical care, gynaecology & neurology, dermatology and women’s health which are its dream segment.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types